Gilead has grown to become a leader in the fight against HIV and has announced efforts to improve access to a new, highly ...

Some people infected with HIV are teeming with virus, but don’t get sick. Their resistive powers probably come from a mix of ...

Fostemsavir plus optimized background therapy was associated with improvements in immune biomarkers among HTE patients with MDR HIV infection.

Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...

Among recipients with HIV, kidney transplantation from donors with HIV is noninferior to that from donors without HIV.

Those include Sunlenca, which is approved for resistant HIV as a twice-yearly injection after an initial oral regimen, and ...

Uganda's efforts to combat the HIV/AIDS epidemic have made significant strides, yet crucial gaps remain, particularly in preventing mother-to-child transmission of the virus.

The companies have presented positive Phase II data during an oral session at IDWeek 2024, in Los Angeles, US.

The national HIV prevalence was 16. 3% among adults aged 15 years and older, translating to an estimated 7. 4 million adults ...

Clarence Peeples is part of a small club in the HIV community. He is using his experiences to help fight the virus among ...

Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...

Three absurdly cheap dividend stocks that are trading at modest multiples of their expected earnings today are Merck ( MRK -0 ...